Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism.

Ladumor MK, Bhatt DK, Gaedigk A, Sharma S, Thakur A, Pearce RE, Leeder JS, Bolger MB, Singh S, Prasad B.

Drug Metab Dispos. 2019 Aug;47(8):818-831. doi: 10.1124/dmd.119.086462. Epub 2019 May 17.

PMID:
31101678
2.

Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults.

Stancil SL, Pearce RE, Tyndale RF, Kearns GL, Vyhlidal CA, Leeder JS, Abdel-Rahman S.

Br J Clin Pharmacol. 2019 May;85(5):960-969. doi: 10.1111/bcp.13884. Epub 2019 Mar 12.

PMID:
30706508
3.

Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

Shakhnovich V, Abdel-Rahman S, Friesen CA, Weigel J, Pearce RE, Gaedigk A, Leeder JS, Kearns GL.

Pediatr Obes. 2019 Jan;14(1). doi: 10.1111/ijpo.12459. Epub 2018 Sep 26.

PMID:
30257076
4.

Development of a UPLC-MS/MS method for quantitation of metronidazole and 2-hydroxy metronidazole in human plasma and its application to a pharmacokinetic study.

Stancil SL, van Haandel L, Abdel-Rahman S, Pearce RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:272-278. doi: 10.1016/j.jchromb.2018.06.024. Epub 2018 Jun 14.

PMID:
29933220
5.

Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver.

Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, Choudhari P, Boberg M, Pearce RE, Gaedigk R, Broeckel U, Leeder JS, Prasad B.

Clin Pharmacol Ther. 2019 Jan;105(1):131-141. doi: 10.1002/cpt.1109. Epub 2018 Jul 12.

PMID:
29737521
6.

Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.

Bhatt DK, Basit A, Zhang H, Gaedigk A, Lee SB, Claw KG, Mehrotra A, Chaudhry AS, Pearce RE, Gaedigk R, Broeckel U, Thornton TA, Nickerson DA, Schuetz EG, Amory JK, Leeder JS, Prasad B.

Drug Metab Dispos. 2018 Jun;46(6):888-896. doi: 10.1124/dmd.118.080952. Epub 2018 Mar 30.

7.

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Burgess KS, Ipe J, Swart M, Metzger IF, Lu J, Gufford BT, Thong N, Desta Z, Gaedigk R, Pearce RE, Gaedigk A, Liu Y, Skaar TC.

Clin Pharmacol Ther. 2018 Jul;104(1):130-138. doi: 10.1002/cpt.892. Epub 2017 Oct 25.

8.

Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B.

J Pharmacol Exp Ther. 2017 Nov;363(2):265-274. doi: 10.1124/jpet.117.243113. Epub 2017 Aug 17.

9.

Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver.

Bhatt DK, Gaedigk A, Pearce RE, Leeder JS, Prasad B.

Drug Metab Dispos. 2017 Sep;45(9):1044-1048. doi: 10.1124/dmd.117.076463. Epub 2017 Jun 12.

10.

Target-distractor synchrony affects performance in a novel motor task for studying action selection.

James S, Bell OA, Nazli MAM, Pearce RE, Spencer J, Tyrrell K, Paine PJ, Heaton TJ, Anderson S, Da Lio M, Gurney K.

PLoS One. 2017 May 5;12(5):e0176945. doi: 10.1371/journal.pone.0176945. eCollection 2017.

11.

Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.

Boberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, Leeder JS, Prasad B.

Drug Metab Dispos. 2017 Feb;45(2):216-223. doi: 10.1124/dmd.116.072652. Epub 2016 Nov 28.

12.

Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation.

Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK Jr, Kearns GL, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee.

J Clin Pharmacol. 2017 Feb;57(2):230-234. doi: 10.1002/jcph.797. Epub 2016 Aug 23. No abstract available.

13.

Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children.

Dinh JC, Pearce RE, Van Haandel L, Gaedigk A, Leeder JS.

Drug Metab Dispos. 2016 Jul;44(7):1070-9. doi: 10.1124/dmd.116.069518. Epub 2016 Apr 6.

14.

Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.

Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, Gaedigk A.

Drug Metab Dispos. 2016 Jul;44(7):948-58. doi: 10.1124/dmd.115.067546. Epub 2015 Nov 25.

15.

In Vitro Hepatic Oxidative Biotransformation of Trimethoprim.

Goldman JL, Leeder JS, Van Haandel L, Pearce RE.

Drug Metab Dispos. 2015 Sep;43(9):1372-80. doi: 10.1124/dmd.115.065193. Epub 2015 Jul 2. Erratum in: Drug Metab Dispos. 2019 Apr;47(4):392.

16.

Variability in Expression of CYP3A5 in Human Fetal Liver.

Vyhlidal CA, Pearce RE, Gaedigk R, Calamia JC, Shuster DL, Thummel KE, Leeder JS.

Drug Metab Dispos. 2015 Aug;43(8):1286-93. doi: 10.1124/dmd.115.064998. Epub 2015 May 15. Erratum in: Drug Metab Dispos. 2016 Sep;44(9):1459.

17.

Plasma ghrelin and liquid gastric emptying in children with functional dyspepsia consistent with post-prandial distress syndrome.

Hijaz NM, Friesen CA, Schurman JV, Pearce RE, Abdel-Rahman SM.

Neurogastroenterol Motil. 2015 Aug;27(8):1120-6. doi: 10.1111/nmo.12591. Epub 2015 May 12.

PMID:
25962328
18.

Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

Tay-Sontheimer J, Shireman LM, Beyer RP, Senn T, Witten D, Pearce RE, Gaedigk A, Gana Fomban CL, Lutz JD, Isoherranen N, Thummel KE, Fiehn O, Leeder JS, Lin YS.

Pharmacogenomics. 2014 Dec;15(16):1947-62. doi: 10.2217/pgs.14.155. Erratum in: Pharmacogenomics. 2015 Jan;16(2):174. Pharmacogenomics. 2015 Jul;16(8):913.

19.

Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children.

McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M.

Biomark Med. 2014;8(10):1189-97. doi: 10.2217/bmm.14.36.

20.

Urinary biomarkers of trimethoprim bioactivation in vivo following therapeutic dosing in children.

van Haandel L, Goldman JL, Pearce RE, Leeder JS.

Chem Res Toxicol. 2014 Feb 17;27(2):211-8. doi: 10.1021/tx4003325. Epub 2014 Jan 13.

PMID:
24380396
21.

The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Pearce RE, Cohen-Wolkowiez M, Sampson MR, Kearns GL.

Drug Metab Dispos. 2013 Sep;41(9):1686-94. doi: 10.1124/dmd.113.052548. Epub 2013 Jun 27.

22.

Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study.

Price KE, Pearce RE, Garg UC, Heese BA, Smith LD, Sullivan JE, Kennedy MJ, Bale JF Jr, Ward RM, Chang TK, Abbott FS, Leeder JS.

Clin Pharmacol Ther. 2011 Jun;89(6):867-74. doi: 10.1038/clpt.2011.47. Epub 2011 May 4.

23.

Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.

Gaedigk A, Isidoro-García M, Pearce RE, Sánchez S, García-Solaesa V, Lorenzo-Romo C, Gonzalez-Tejera G, Corey S.

Eur J Clin Pharmacol. 2010 Sep;66(9):859-64. doi: 10.1007/s00228-010-0831-4. Epub 2010 May 16. Erratum in: Eur J Clin Pharmacol. 2011 Jan;67(1):101. Dosage error in article text.

PMID:
20473659
24.

Characterization of delayed liquid gastric emptying in children by the (13)C-acetate breath test.

Jones BL, Pearce RE, Abdel-Rahman SM, Friesen CA, James LP, Kearns GL.

J Breath Res. 2009 Dec;3(4):047004. doi: 10.1088/1752-7155/3/4/047004. Epub 2009 Nov 27.

PMID:
21386201
25.

Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin.

Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B.

Biochem Pharmacol. 2009 Jan 15;77(2):238-47. doi: 10.1016/j.bcp.2008.10.005. Epub 2008 Oct 15.

26.

Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL.

Clin Pharmacol Ther. 2008 Dec;84(6):674-8. doi: 10.1038/clpt.2008.185. Epub 2008 Oct 8. No abstract available.

27.

Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement.

Kennedy MJ, Davis DA, Smith N, Gaedigk A, Pearce RE, Kearns GL.

Clin Ther. 2008 Sep;30(9):1687-99. doi: 10.1016/j.clinthera.2008.09.012.

PMID:
18840375
28.

Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype.

Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI.

J Clin Pharmacol. 2008 Sep;48(9):1041-51. doi: 10.1177/0091270008319709.

29.

Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine.

Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS.

Drug Metab Dispos. 2008 Aug;36(8):1637-49. doi: 10.1124/dmd.107.019562. Epub 2008 May 7.

30.

CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile.

Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA.

Drug Metab Dispos. 2008 Mar;36(3):490-9. Epub 2007 Dec 20.

31.

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS.

Clin Pharmacol Ther. 2008 Feb;83(2):234-42. Epub 2007 Oct 31.

PMID:
17971818
32.

Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.

Gaedigk A, Eklund JD, Pearce RE, Leeder JS, Alander SW, Phillips MS, Bradford LD, Kennedy MJ.

Clin Pharmacol Ther. 2007 Jun;81(6):817-20. Epub 2007 Mar 28.

PMID:
17392730
33.

Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS.

Clin Pharmacol Ther. 2007 Apr;81(4):510-6. Epub 2007 Feb 14.

PMID:
17301735
34.

Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants.

Blake MJ, Abdel-Rahman SM, Pearce RE, Leeder JS, Kearns GL.

Pediatr Res. 2006 Dec;60(6):717-23. Epub 2006 Oct 25.

PMID:
17065585
35.

Variability of CYP2J2 expression in human fetal tissues.

Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA, Zeldin DC, Leeder JS.

J Pharmacol Exp Ther. 2006 Nov;319(2):523-32. Epub 2006 Jul 25.

36.

Biotransformation of fluticasone: in vitro characterization.

Pearce RE, Leeder JS, Kearns GL.

Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24.

PMID:
16565171
37.

Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene.

Pearce RE, Uetrecht JP, Leeder JS.

Drug Metab Dispos. 2005 Dec;33(12):1819-26. Epub 2005 Aug 31.

PMID:
16135660
38.

Variability of CYP3A7 expression in human fetal liver.

Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE.

J Pharmacol Exp Ther. 2005 Aug;314(2):626-35. Epub 2005 Apr 21.

PMID:
15845858
39.

Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

Gaedigk A, Bhathena A, Ndjountché L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, Rogan PK, Leeder JS.

Pharmacogenomics J. 2005;5(3):173-82. Erratum in: Pharmacogenomics J. 2005;5(4):276. Rogan, PK [added].

40.
41.

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.

Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A.

Drug Metab Dispos. 2002 May;30(5):595-601.

PMID:
11950793
42.
43.

Effects of musk xylene and musk ketone on rat hepatic cytochrome P450 enzymes.

Lehman-McKeeman LD, Caudill D, Vassallo JD, Pearce RE, Madan A, Parkinson A.

Toxicol Lett. 1999 Dec 20;111(1-2):105-15.

PMID:
10630706
44.

Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.

Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A.

Arch Biochem Biophys. 1996 Jul 15;331(2):145-69.

PMID:
8660694
45.

Identification of the human P450 enzymes involved in lansoprazole metabolism.

Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A.

J Pharmacol Exp Ther. 1996 May;277(2):805-16.

PMID:
8627562
46.

'Anesthetic' doses of fentanyl.

Pearce RE.

Arch Surg. 1988 Dec;123(12):1525. No abstract available.

PMID:
3190433
47.
48.

trans-6-Hexadecenoic acid in the spadefish Chaetodipterus faber.

Pearce RE, Stillway LW.

Lipids. 1976 Mar;11(3):247-8.

PMID:
1263768

Supplemental Content

Loading ...
Support Center